GLP-1 receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon)are prescribed for type 2 diabetes management and, in some formulations, for weight management in adults with obesity or overweight with comorbidities
As lower doses than recommended for weight loss have not been tested, we cannot answer this question yet
The program is designed for adults who are looking for a fully virtual, no-insurance-required path to licensed GLP-1 treatment - and who want ongoing provider access as part of the program, not just at signup
When you participate in one of our programs, you are not just getting a prescription